Journal
CANCER TREATMENT REVIEWS
Volume 74, Issue -, Pages 29-34Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2019.01.007
Keywords
Early breast cancer; Extended adjuvant endocrine therapy; Aromatase inhibitor; Hormone receptor-positive breast cancer; Luminal breast cancer
Categories
Ask authors/readers for more resources
Patients with luminal early breast cancer are at risk of relapse, even after five years of adjuvant endocrine therapy. To date, no biomarkers have been clinically validated to identify those patients at risk of late recurrence, who might benefit from extended adjuvant endocrine therapy. In recent decades, multiple clinical trials have tested the role of extending adjuvant endocrine therapies in patients with luminal disease. However, the data currently at our disposal are conflicting. This article reviews all the major trials concerning extended adjuvant endocrine regimens, and formulates some general conclusions and hypotheses of future study.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available